A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
The primary objective of this study is to determine the relative bioavailability of treprostinil (TRE) between the TPIP F2 and TPIP F3 at 3 capsule strengths, dose A, dose B, and dose C, in healthy participants following a single inhalation of TPIP dose.
Epistemonikos ID: 67dbabf34d809f58637f36cdac7236d80df41fbd
First added on: Aug 05, 2025